Adam’s Take

Adam's Take Adam Feuerstein

STAT Plus: The failure of a cancer drug study leaves Cel-Sci on the brink of collapse

Adam's Take Adam Feuerstein

STAT Plus: FDA issues major rebuke to CytoDyn over claims on Covid-19 drug

Adam's Take Adam Feuerstein

STAT Plus: Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug

Adam's Take Adam Feuerstein

STAT Plus: Fibrogen’s data manipulation scandal came with questions. There need to be answers

Adam's Take Adam Feuerstein

STAT Plus: The long wait for Cel-Sci to finally admit its cancer drug doesn’t work

Adam's Take Adam Feuerstein

STAT Plus: A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists

Adam's Take Adam Feuerstein

STAT Plus: CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment

Adam's Take Adam Feuerstein

STAT Plus: Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

Adam's Take Adam Feuerstein

STAT Plus: Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list

Adam's Take Adam Feuerstein

STAT Plus: Why did this small biotech blow up? Because spinning bad drug data never works

Adam's Take Adam Feuerstein

STAT Plus: Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles

Adam's Take Adam Feuerstein

STAT Plus: Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug

Adam's Take Adam Feuerstein

STAT Plus: Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Adam's Take Adam Feuerstein

STAT Plus: Applied Therapeutics’ muted response to a clinical hold speaks volumes

Adam's Take Adam Feuerstein

STAT Plus: CytoDyn is in financial and clinical distress, newly filed annual report shows

Adam's Take Adam Feuerstein

STAT Plus: CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure

Adam's Take Adam Feuerstein

STAT Plus: CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

Adam's Take Adam Feuerstein

STAT Plus: Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response

Adam's Take Adam Feuerstein

STAT Plus: Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

Adam's Take Adam Feuerstein

STAT Plus: FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

Adam's Take Adam Feuerstein

STAT Plus: A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

Adam's Take Adam Feuerstein

STAT Plus: ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress

Adam's Take Adam Feuerstein

STAT Plus: Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock

Adam's Take Adam Feuerstein

STAT Plus: With high hopes for its Covid-19 vaccine, Moderna stock value requires nearly mythical leap of faith

Adam's Take Adam Feuerstein

STAT Plus: CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed

Biotech Adam Feuerstein

STAT Plus: CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions

Adam's Take Adam Feuerstein

STAT Plus: Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock

Adam's Take Adam Feuerstein

STAT Plus: Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last

Adam's Take Adam Feuerstein

STAT Plus: Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence